Arrowhead Pharmaceuticals (ARWR) Cash & Current Investments (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Cash & Current Investments data on file, last reported at $1.8 billion in Q1 2026.

• Quarterly Cash & Current Investments rose 62.57% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 62.57% YoY) and the FY2025 annual result came in at $919.4 million, up 35.01% from the prior year.
• Cash & Current Investments advanced to $1.8 billion in Q1 2026, from $916.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $1.8 billion in Q1 2026 to a low of $108.0 million in Q3 2022.
• A 5-year average of $623.7 million and a median of $501.8 million in 2022 frame the typical range for Cash & Current Investments.
• The widest YoY moves for Cash & Current Investments: up 345.93% in 2022, down 65.29% in 2022.
• Tracing ARWR's Cash & Current Investments over 5 years: stood at $501.8 million in 2022, then tumbled by 56.1% to $220.3 million in 2023, then surged by 150.95% to $552.9 million in 2024, then jumped by 65.79% to $916.6 million in 2025, then jumped by 94.64% to $1.8 billion in 2026.
• The last three Cash & Current Investments figures came in at $1.8 billion (Q1 2026), $916.6 million (Q4 2025), and $919.4 million (Q3 2025), per Business Quant data.